Evidence map›Paper›PMID 41667911›Full record

ArticleAAPS PharmSciTech2026

Analysis of the Correlation Between Membrane Permeability in RPMI 2650 Cells and Human Nasal Absorption.

Tokio Morita, Toshiaki Tsuchitani, Hiroyuki Yoshida, Naomi Tomita, Yoji Sato

Abstract read
PubMed Publisher
In one paragraph

Article in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Tokio MoritaDivision of Drugs, National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-Ku, Kawasaki-Shi, Kanagawa, 210-9501, Japan. morita_tokio@nihs.go.jp.ORCID http://orcid.org/0000-0001-5951-2981
Toshiaki TsuchitaniDivision of Pharmaceutics, Faculty of Pharmacy, Keio University, 1-5-30 Shibakoen, Minato-Ku, Tokyo, 105-8512, Japan.ORCID http://orcid.org/0000-0002-7257-3196
Hiroyuki YoshidaDivision of Drugs, National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-Ku, Kawasaki-Shi, Kanagawa, 210-9501, Japan.ORCID http://orcid.org/0000-0002-9223-5055
Naomi TomitaDivision of Drugs, National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-Ku, Kawasaki-Shi, Kanagawa, 210-9501, Japan.
Yoji SatoDivision of Drugs, National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-Ku, Kawasaki-Shi, Kanagawa, 210-9501, Japan.ORCID http://orcid.org/0000-0002-9889-1272

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nasal drug delivery offers several advantages, such as rapid onset and avoidance of hepatic first-pass metabolism, making it a promising option for delivering drugs both locally and systemically. In the early phases of pharmaceutical development, predictive tools for nasal absorption are critical for selecting suitable candidates. This study evaluates the utility of RPMI 2650 cells as an in vitro model for predicting nasal drug absorption. First, we confirmed the reproducibility of membrane permeability across two air-liquid interface culture conditions (shifted on days 1 and 3), demonstrating consistent permeability profiles and agreement with previously reported P

Indexed as

Cell Membrane PermeabilityNasal AbsorptionNasal MucosaAdministration, IntranasalBiological AvailabilityCell LineHumansPermeabilityReproducibility of Resultsin vitro-in vivo correlationNasal absorptionNasal fraction absorbedRPMI 2650 cells

Identifiers

PMID41667911

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.